TORONTO, Dec. 19, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company") a pharmaceutical company specialized in precision-based cannabinoids, welcomes U.S. President Donald Trump’s executive order to expedite the reclassification of cannabis under the U.S. Controlled Substances Act from Schedule I to Schedule III (the "Order"). 1 This change... Read More

TORONTO, Dec. 10, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) (“MediPharm” or the “Company”), a pharmaceutical company specialized in precision-based cannabinoids, today announced that Shelley Potts will be stepping down from the Company’s Board of Directors (the “Board”), effective December 31, 2025. The Company also announced that Michael Bumby will be rejoining the Board, effective... Read More

TORONTO, Dec. 04, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company"), a pharmaceutical company specialized in precision-based cannabinoids, is pleased to announce the completion of the Company's first shipment to France. This milestone follows a production agreement with an international medicinal cannabis organization. This strategic... Read More

TORONTO, Nov. 14, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) (“ MediPharm ” or the “ Company ”), a pharmaceutical company specialized in precision-based cannabinoids, today announced that the Superior Court of Justice – Ontario (Commercial List) (the “ Court ”) has fully dismissed the statement of claim (CV-25-00742450-0000) (the “ Claim ”) issued by Apollo Technology Capital... Read More

Q3 2025 Revenue of $11.4 Million, an Increase of 17% over Q3 2024 83% Growth in Year-Over-Year Revenue for International Medical Cannabis International Medical sales now 56% of Total Revenue Increased Cash Balance of $10.6 Million at the end of Q3 2025 Operating Expenses Decreased 19% Year-Over-Year Management to Host Conference Call / Webcast on November 13 th , 2025 at 10:00 am ET TORONTO, Nov. 13, 2025 (GLOBE NEWSWIRE) --... Read More

TORONTO, Nov. 10, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS ) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company") a pharmaceutical company specialized in precision-based cannabinoids, is pleased to announce it will release its third quarter financial results for the three and nine months ended September 30 th , 2025, before markets open on Thursday, November 13 th , 2025. MediPharm Labs... Read More

Q2 Revenue of $11.8 Million, an Increase of 14% over Q2 2024 50% Growth in Revenue for International Medical Cannabis International Medical sales now 57% of Total Revenue Cash Balance of $10.4 Million at the end of Q2, Increased from $8.4 Million in Q1 2025 Management to Host Conference Call / Webcast on August 14 th , 2025 at 10:00 am ET TORONTO, Aug. 14, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS ) (OTCQB:... Read More

MediPharm Labs holds unique US Food and Drug Administration (FDA) site registration in relation to the manufacturing and release of pharmaceutical cannabis products. MediPharm is the only US FDA Audited purpose-built commercial cannabis facility in Canada . One of a handful globally. The possible rescheduling of cannabis in the US opens new opportunities for MediPharm in categories where the Company maintains a competitive... Read More

TORONTO, Aug. 11, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS ) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company") a pharmaceutical company specialized in precision-based cannabinoids, is pleased to announce it will release its second quarter financial results for the three and six months ended June 30 th , 2025, before markets open on Thursday, August 14 th , 2025. MediPharm Labs... Read More

TORONTO, July 24, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company"), a pharmaceutical company specializing in precision-based cannabinoids, is pleased to announce it has launched the new Shake & Puff CBN THC Nighttime Inhaler in Canada. This... Read More

TORONTO, June 17, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) (“ MediPharm ” or the “ Company ”), a pharmaceutical company specialized in precision-based cannabinoids, today announced the results of matters voted on at its annual and special meeting (the “ Meeting ”) of holders of common shares (" Shareholders ") held today. There were 146 Shareholders represented virtually or by proxy... Read More

TORONTO, June 16, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) (“ MediPharm ” or the “ Company ”), a pharmaceutical company specialized in precision-based cannabinoids, wishes to respond to a misleading press release published earlier today by Apollo Technology Capital Corporation (“ Apollo ”) prematurely claiming that it considers the results of the annual and special meeting of... Read More

MediPharm Labs’ Board’s Material and Unprecedented Breaches of Securities Laws Are Part of Their Undoing Apollo Capital’s Entire Slate of Board Nominees Constitute the New Board of Directors for MediPharm Labs Effective Today TORONTO, June 16, 2025 (GLOBE NEWSWIRE) -- Apollo Technology Capital Corporation (“Apollo Capital” or “Apollo”), which together with its affiliates and associates collectively is one of the largest... Read More

TORONTO, June 13, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) (“ MediPharm ” or the “ Company ”), a pharmaceutical company specialized in precision-based cannabinoids, today announced that leading independent proxy voting and corporate governance advisory firm Glass, Lewis & Co. LLC (“ Glass Lewis ”) published a report on June 12, 2025 recommending that MediPharm shareholders vote the... Read More

Shareholders Urged to Vote for Proven Strategy and Team, Reject Dissident’s Inadequate Plan and Nominees TORONTO, June 11, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) (“ MediPharm ,” the “ Company ,” “ we ” or “ us ”), a pharmaceutical company specialized in precision-based cannabinoids, today reminded its shareholders that the deadline is approaching to cast your vote for the upcoming... Read More

TORONTO, June 11, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) (“ MediPharm ” or the “ Company ”), a pharmaceutical company specialized in precision-based cannabinoids, today announced that the Superior Court of Justice – Ontario (Commercial List) (the “ Court ”) has fully dismissed the application (CV-25-00743454-00CL) (the “ Application ”) issued by Apollo Technology Capital... Read More

TORONTO, June 11, 2025 (GLOBE NEWSWIRE) -- Apollo Technology Capital Corporation (“Apollo Capital”), which together with its affiliates and associates collectively is one of the largest shareholders of MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) (“MediPharm”, “MediPharm Labs”, or the “Company”), owning approximately 3% of the Company’s common stock, today issued a presentation to set forth their ambitious plan... Read More

McCutcheon Agrees with Apollo that Urgent Change is Needed, including Complete Turnover at the Board Level after Years of Value-Destruction Apollo Capital Announces Filing of Circular Addendum to Reflect McCutcheon’s Endorsement SHAREHOLDERS ARE URGED TO VOTE THE GOLD CARD “FOR” APOLLO CAPITAL’S SIX DIRECTOR NOMINEES AND NOT VOTE MEDIPHARM’s GREEN CARD TORONTO, June 09, 2025 (GLOBE NEWSWIRE) -- Apollo Technology Capital... Read More

TORONTO, June 05, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm"), a pharmaceutical company specialized in precision-based cannabinoids, announced the closing of the sale of its Hope, British Columbia facility (the “Hope Facility”) to Rubicon Organics Inc. (TSXV: ROMJ) (OTCQX: ROMJF) for $4.5 million in cash (the “Transaction”). In parallel, the Company is expanding annual... Read More

TORONTO, June 02, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) (“ MediPharm ” or the “ Company ”), a pharmaceutical company specialized in precision-based cannabinoids, today announced that Institutional Shareholder Services (“ ISS ”) published a report on May 30, 2025 (the “ ISS Report ”) recommending that MediPharm shareholders vote the GREEN Proxy or voting instruction form FOR the... Read More

Demands Management’s Board Nominees John Medland and Emily Jameson Withdraw Immediately or Face Public Complicity in Ongoing Alleged Systemic Violations of Securities Laws URGES SHAREHOLDERS TO VOTE THE GOLD PROXY CARD "FOR" APOLLO CAPITAL'S SIX DIRECTOR NOMINEES AND DISREGARD MEDIPHARM LABS’ GREEN PROXY CARD TORONTO, May 30, 2025 (GLOBE NEWSWIRE) -- Apollo Technology Capital Corporation (“Apollo Capital”), which together... Read More

TORONTO, May 29, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE:MLZ) (“ MediPharm ” or the “ Company ”), a pharmaceutical company specialized in precision-based cannabinoids, today confirmed that the Company is aware of the news release issued by Apollo Technology Capital Corporation (“ Apollo ”) on May 29, 2025 making baseless allegations of malfeasance against the Company. These patently... Read More

TORONTO, May 28, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (" MediPharm " or the " Company "), a pharmaceutical company specialized in precision-based cannabinoids, today issued a Letter to Shareholders from the Company’s Board of Directors (the “Letter”). The Letter is a response to the amended and restated... Read More

TORONTO, May 26, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company"), a pharmaceutical company specialized in precision-based cannabinoids, is pleased to announce it has begun production on novel cannabis metered dose inhalers for the EU and the United Kingdom, made to global pharmaceutical standards and distributed by Blackpoint Limited... Read More

TORONTO, May 23, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (“MediPharm”, the “Company”, or “we”), a pharmaceutical company specialized in precision-based cannabinoids, today provided its shareholders with information related to three of the six directors (the “ Dissident Nominees ”) nominated by Apollo Technology Capital Corporation (“ Apollo ”) to stand for election at MediPharm’s Annual and Special Meeting... Read More

MediPharm Labs Board Continues to Obstruct the Appointment and Oversight of an Independent Chair Failure to Appoint an Independent Chair to Oversee the Election of Directors at the Annual Meeting Prevents Shareholders from Exercising their Legal Right to Hold the Current Board Accountable for their Epic Failures Board Made No Attempt to Engage with Apollo Capital; Instead Resorted to Continued Campaign of Misdirection and... Read More

TORONTO, May 22, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (" MediPharm " or the " Company "), a pharmaceutical company specialized in precision-based cannabinoids, is pleased to announce the removal of all conditions precedent, related to its previously-announced agreement (the “ Purchase Agreement ”) for the sale of MediPharm’s facility in Hope, BC, (“ Hope Facility ”) to Rubicon Organics Inc. (TSXV: ROMJ )... Read More

TORONTO, May 21, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) ("MediPharm" or the "Company"), a pharmaceutical company specialized in precision-based cannabinoids, today alerted its shareholders to publicly available information about Regan McGee, the controlling shareholder, director, Chairman and CEO of Apollo Technology Capital Corporation (“ Apollo ”), a dissident MediPharm shareholder. Apollo filed an... Read More

Launches Campaign Website at www.CureMediPharm.com , Which Articulates 5-Pillar Plan to Rebuild Company Details How MediPharm Labs is Hemorrhaging Money at an Alarming Rate and is on Pace to Run Out of Cash by November 2025 Exorbitant Executive Compensation Packages Despite Persistent Losses Demonstrate a Board and Management Team Misaligned with Shareholders' Best Interests Board Cannot Be Trusted After Costing Shareholders... Read More

Company Has Suspended Calls Since the Second Quarter of 2024 to Avoid Facing the Music for Board's and Management Team's Destruction of 99% of Stock's Value, Costing Shareholders $1 Billion Conference Call is a Blatant, Self-Serving Reaction by a Management Team Running Scared Following Apollo Capital's Intention to Nominate Six Highly Qualified Directors to MediPharm's Board Shareholders Deserve Answers From Management... Read More

Achieves Positive Adjusted EBITDA (1) Revenue of $10.8 Million , an Increase of 11% over Q1 2024 87% Growth in International Medical Cannabis Revenue, Forming 55% of Total Revenue Gross Profit of $4.2 million , or 39% of Total Revenue, Improved Significantly over Q1 2024 Management to Host Conference Call / Webcast on May 14,... Read More

TORONTO , May 9, 2025 /CNW/ - MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company") a pharmaceutical company specialized in precision-based cannabinoids, is pleased to announce it will release its first quarter financial results for the period ended March 31, 2025, before markets open on Wednesday, May 14, 2025. MediPharm Labs executive management team will also host a... Read More

Believes Board Change is Urgently Needed: Under the Current Board and Management, MediPharm Stock Price is Down More Than 99%, Costing Shareholders Nearly $1 Billion MediPharm's Board Cannot be Trusted to Create Shareholder Value or Oversee Management! Company Leadership Lacks Any Credible Strategic Plan and Has Made Numerous... Read More

Annual Net Revenue Increase of 27% to $42M , Driven by Record $18M International Medical Cannabis Revenue and Approaching Positive Adjusted EBITDA (1) for Q4. TORONTO , March 31, 2025 /CNW/ - MediPharm Labs Corp . (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company") a pharmaceutical company... Read More

TORONTO , March 26, 2025 /CNW/ - MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company") a pharmaceutical company specialized in precision-based cannabinoids, is pleased to announce it will release its full year and fourth quarter financial results for the three and twelve months ended December 31 st , 2024, before markets open on Monday, March 31 st , 2025. An updated... Read More

TORONTO , Feb. 10, 2025 /CNW/ - MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) ("MediPharm", "MediPharm Labs" or the "Company") has terminated the previously announced sale of its facility in Napanee, Ontario (the "Napanee Facility") to Kensana Health Inc. ("Kensana Health"), which was to be completed through the sale of the Company's wholly-owned subsidiary ABcann Medicinals Inc. ("ABcann") to Kensana Health pursuant to... Read More

TORONTO , Jan. 16, 2025 /CNW/ - MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) ("MediPharm", "MediPharm Labs" or the "Company") is pleased to provide an update with respect to the previously announced sale of its facility in Napanee, Ontario (the "Napanee Facility") to be completed pursuant to the terms of a share purchase agreement (the "Purchase Agreement") entered into with Kensana Health Inc. ("Kensana Health") through... Read More

MediPharm Labs expands its Brazilian presence where the medical cannabis market is estimated to be worth $198 million in 2024, serving over 670,000 patients. 1 Products include full-spectrum, GMP sublingual oral solutions with extensive pharmaceutical validation and characterization. Teuto is one of Brazil's largest pharmaceutical manufacturers of both generic and branded medicines, with an extensive portfolio of oncologic... Read More

TORONTO , Dec. 17, 2024 /CNW/ - MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) ("MediPharm", "MediPharm Labs" or the "Company") and Kensana Health Inc. ("Kensana Health") are pleased to announce that they have entered into a share purchase agreement (the "Purchase Agreement") for the purchase and sale of MediPharm's facility in Napanee, Ontario (the "Napanee Facility") through a disposition of all of the Company's indirect... Read More

Strong Growth in International GMP Medical Markets TORONTO , Nov. 14, 2024 /PRNewswire/ - MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company") a pharmaceutical company specialized in precision-based cannabinoids announced its financial results for the three and nine months ended September 30, 2024 . Key Highlights Adjusted EBITDA (1) : Negative $743K in the three months... Read More

Strong Growth in International GMP Medical Markets TORONTO , Nov. 14, 2024 /CNW/ - MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company") a pharmaceutical company specialized in precision-based cannabinoids announced its financial results for the three and nine months ended September 30, 2024 . Key Highlights Adjusted EBITDA (1) : Negative $743K in the three months ended... Read More

TORONTO , Nov. 11, 2024 /CNW/ - MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company") a pharmaceutical company specialized in precision-based cannabinoids, is pleased to announce it will release its third quarter financial results for the three and nine months ended September 30, 2024 , before markets open on Thursday, November 14, 2024 . An updated company presentation... Read More

TORONTO , Oct. 17, 2024 /CNW/ - MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) ("MediPharm", "MediPharm Labs" or the "Company"), a specialized, research-driven company focused on pharmaceutical-quality cannabis extraction and cannabis based health products, is announcing that President and Co-Founder Keith Strachan will be stepping down from his management position effective December 31, 2024 . Keith will continue to... Read More

TORONTO , Aug. 14, 2024 /CNW/ - MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company") a pharmaceutical company specialized in precision-based cannabinoids announced its financial results for the three and six months ended June 30, 2024 ("Q2 2024"). Key Highlights Adjusted EBITDA (1) : Negative $124K in Q2 2024, significantly improved from negative $949K during the three... Read More

TORONTO , Aug. 8, 2024 /CNW/ - MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company") a pharmaceutical company specialized in precision-based cannabinoids, is pleased to announce it will release its second quarter financial results for the period ended June 30, 2024 , before markets open on Wednesday, August 14, 2024 . MediPharm Labs executive management team will also... Read More

TORONTO , June 26, 2024 /CNW/ - MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company"), a pharmaceutical company specialized in precision-based cannabinoids, today announced the results of matters voted on at its annual meeting of holders of common shares ("Shareholders") held on Wednesday, June 26, 2024 (the "Meeting"). The voting results for each of the matters presented... Read More

MediPharm has licenced global manufacturing, distribution, and sales rights of the novel advanced medical cannabis technology from Remidose Aerosols. Products include metered dose inhalers and aerosol sublingual sprays. MediPharm will assume existing Remidose sales allowing for immediate revenue opportunity. Transaction is non-dilutive, with 100% performance-based payment through a royalty model. TORONTO , June 20, 2024... Read More

Completes Major Steps Towards Profitability with Best Revenue and Adjusted EBITDA in Over Three Years TORONTO , May 15, 2024 /CNW/ - MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company") a pharmaceutical company specialized in precision-based cannabinoids announced its financial results for the three months ended March 31, 2024 . Select Highlights Revenue increased 67% to... Read More

TORONTO , May 8, 2024 /CNW/ - MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company") a pharmaceutical company specialized in precision-based cannabinoids, is pleased to announce it will release its first quarter financial results for the period ended March 31, 2024 , before markets open on Wednesday, May 15, 2024 . MediPharm Labs executive management team will also host a... Read More

TORONTO , March 27, 2024 /CNW/ - MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company") a pharmaceutical company specialized in precision-based cannabinoids, has released and hosted a conference call regarding its full year and fourth quarter financial results for the period ended December 31, 2023 . MediPharm Labs executive management team thanks those were able to join... Read More

Annual Revenue and Adjusted EBITDA Improve by 50% TORONTO , March 27, 2024 /CNW/ - MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company") a pharmaceutical company specialized in precision-based cannabinoids, today announced its financial results for the full year and three... Read More

German federal states have voted to decriminalize the personal cultivation and use of cannabis. The new legislation that takes effect April 1, 2024 , also removes medical cannabis from the German narcotic list, removing access barriers for patients. TORONTO , March 25, 2024 /CNW/ - MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company") a pharmaceutical company specialized... Read More

TORONTO , March 22, 2024 /CNW/ - MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company") a pharmaceutical company specialized in precision-based cannabinoids, is pleased to announce it will release its full year and fourth quarter financial results for the period ended December 31, 2023 , before markets open on Wednesday, March 27, 2024 . MediPharm Labs executive management... Read More

MediPharm Labs is the first purpose-built pharmaceutical cannabis company in North America to receive a GMP certificate from the Brazilian Health Regulatory Agency (ANVISA), for production of cannabis finished goods. This strengthens MediPharm Labs' position in Brazil to manufacture both API and end products for Brazilian medical cannabis patients. Brazil , with a population of 215M , has seen tremendous growth in medical... Read More

TORONTO , Dec. 22, 2023 /CNW/ - MediPharm Labs Corp . (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company") a pharmaceutical company specialized in precision-based cannabinoids, today announced an update regarding its Board of Directors and employee stock issuance. Effective immediately Miriam McDonald has resigned from her position from the Board of Directors. As a founding board member of... Read More

Achieves Higher Gross Margin, Moves Closer to Profitability TORONTO , Nov. 14, 2023 /PRNewswire/ - MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company") a pharmaceutical company specialized in precision-based cannabinoids, today announced its financial results for the three... Read More

TORONTO , Nov. 8, 2023 /CNW/ - MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company") a pharmaceutical company specialized in precision-based cannabinoids, is pleased to announce it will release its third quarter financial results for the three and nine month periods ended September 30, 2023 , before markets open on Tuesday, November 14, 2023 . MediPharm's executive... Read More

TORONTO , Oct. 25, 2023 /CNW/ - MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company") a company specialized in precision-based cannabinoids, is pleased to announce it has now received $7.27 Million in gross cash proceeds from the settlement agreement announced on October 2, 2023 (the "Settlement Agreement") to resolve a claim in connection with a commercial agreement... Read More

TORONTO , Oct. 2, 2023 /CNW/ - MediPharm Labs Corp . (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company") a company specialized in precision-based cannabinoids, is pleased to announce it has entered into a settlement agreement on September 29, 2023 (the "Settlement Agreement") to resolve a claim in connection with a commercial agreement dispute, for a total consideration value of $9,000,000... Read More

The launch includes GMP strain-specific full spectrum cannabis oil and inhalation cartridge products to be distributed to patients under the MediPharm Labs Beacon Medical brand. As of July 2023 , all Australian medical cannabis products must meet strict pharmaceutical GMP standards. MediPharm Labs is one of the few companies already meeting these GMP requirements. TORONTO , Sept. 27, 2023 /CNW/ - MediPharm Labs Corp. (TSX:... Read More

MediPharm Labs and Shelter Cannabis Brands have terminated their royalty agreement with a one-time cash payment. Agreement includes the elimination of ongoing royalty payments, for a one-time lump sum payment. TORONTO , Sept. 20, 2023 /CNW/ - MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company") a company specialized in precision-based cannabinoids, is pleased to announce... Read More

MediPharm Labs sold vacant land in Napanee, Ontario last utilized in 2021 for outdoor cannabis growing activities. The land was acquired by MediPharm as part of the VIVO Cannabis acquisition in April 2023 . The net cash proceeds of $1.9 million adds non-dilutive capital to MediPharm's strong balance sheet. The $1.9 million cash is in addition to $7 million annualized synergies already executed since the closing of the VIVO... Read More

MediPharm Labs wholly owned subsidiary Harvest Medicine has published a study in the peer-reviewed American Journal of Endocannabinoid Medicine. This is the largest peer reviewed published study of its kind on Fibromyalgia and cannabis, with over 800 patient assessments. Between baseline and follow-up appointments, 75% of patients saw a significant decrease in their self-reported illness severity and the study reported... Read More

TORONTO , Aug. 14, 2023 /CNW/ - MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company") a pharmaceutical company specialized in precision-based cannabinoids, today announced its financial results for the three months ended June 30, 2023 . Second Quarter 2023 – Select Highlights Completed our first commercial delivery to the United States . The delivery was comprised of... Read More

TORONTO , Aug. 10, 2023 /CNW/ - MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company") a pharmaceutical company specialized in precision-based cannabinoids, is pleased to announce it will release its second quarter financial results for the three month period ended June 30, 2023 , before markets open on Monday, August 14, 2023 . MediPharm's executive management team will... Read More

MediPharm announces first delivery of pharmaceutical cannabis product for NIH funded clinical trial, following import permit from the US Drug Enforcement Agency (DEA) and Health Canada export permit. MediPharm has provided a full response to the US Food and Drug Administration (FDA) in relation to the initial pre-approval site inspection of its Barrie facility regarding a new Drug Master File (DMF) being referenced in a... Read More

TORONTO , June 22, 2023 /CNW/ - MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company"), a pharmaceutical company specialized in precision-based cannabinoids, today announced that, at the request of the Company's board of directors and following the recommendation of the audit committee, the Company's board of directors have accepted the resignation of KPMG LLP as the... Read More

TORONTO , May 15, 2023 /CNW/ - MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company") a pharmaceutical company specialized in precision-based cannabinoids, today announced its financial results for the three months ended March 31, 2023 . First Quarter 2023 – Select Highlights Progress Towards Profitability Achieved strongest EBITDA (1) in two years as compared to prior... Read More

TORONTO , May 10, 2023 /CNW/ - MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company") a pharmaceutical company specialized in precision-based cannabinoids, is pleased to announce it will release its first quarter financial results for the three month period ended March 31, 2023 , before markets open on Monday, May 15, 2023 . MediPharm's executive management team will also... Read More

MediPharm Labs begins restructuring immediately following completion of its acquisition of VIVO and reiterates confidence in $7 to 9M of projected annualized synergies. (1)(2)(3)(4) MediPharm Labs appoints Michael Bumby , former Chief Financial Officer of VIVO, to the Board of Directors of MediPharm. BARRIE, ON , April 13, 2023 /CNW/ - MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) ("MediPharm Labs", "MediPharm"... Read More

TORONTO , March 31, 2023 /CNW/ - MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company") a pharmaceutical company specialized in precision-based cannabinoids, today announced its financial results for the three and twelve months ended December 31, 2022 . 2022 – Select Highlights Revenue Growth in Key Segments In 2022, MediPharm saw optimized sales segment focus shift to... Read More

TORONTO , March 28, 2023 /CNW/ - MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company") a pharmaceutical company specialized in precision-based cannabinoids, is pleased to announce it will release fourth quarter financial results for the three and twelve month period ended December 31, 2022 before markets open on Friday, March 31, 2023 . MediPharm's executive management... Read More

BARRIE, ON , March 21, 2023 /CNW/ - MediPharm Labs Corp . (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) ("MediPharm", or "MediPharm Labs") is pleased to announce that the shareholders of MediPharm (the "Shareholders") have approved the plan of arrangement under section 192 of the Canada Business Corporations Act (the "Arrangement"), previously announced on December 22, 2022 , pursuant to which MediPharm will acquire all of the... Read More

MediPharm Labs shares progress on clinical trials, including the provision of clinical trial materials and research support to multiple partners. Research support consists of both product and services for partner studies across various indications. MediPharm Labs participation ranges from full drug development support to FDA approved clinical trial materials. MediPharm Labs GMP Drug Establishment License, DMF capability,... Read More

BARRIE, ON , Feb. 21, 2023 /CNW/ - MediPharm Labs Corp . (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) ("MediPharm", or "MediPharm Labs") is pleased to announce the mailing of a joint management information circular of MediPharm and VIVO Cannabis Inc. ("VIVO") dated February 6, 2023 (the "Circular") and related documents for the special meeting of MediPharm shareholders to be held virtually at 1:00 p.m. ( Toronto time) on March 21,... Read More

Two global leaders in the medical wellness cannabis industry expected to combine complementary strengths of diversified revenue in multiple markets and channels to create a pro-forma Combined Company with over $50M in annualized revenue, based on Q3 2022. (1)(2)(3)(4) Pro-forma Combined Company is expected to have positive EBITDA (5) synergies of between $7M to $9M on an annualized basis within 12 months closing of the... Read More

For the second year MediPharm Labs' pharma-quality CBD dominant oil line has been awarded the CBD Brand of the year by KIND Magazine. MediPharm Labs was also awarded the CBN Product of the Year and the Kindest Health and Wellness Brand of the Year Awards. MediPharm Labs' wellness products, lead by our CBD oils, have seen steady revenue and popularity growth in 2022, as it's second full year in market. BARRIE, ON , Dec. 8,... Read More

TORONTO , Nov. 14, 2022 /CNW/ - MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company") a pharmaceutical company specialized in precision-based cannabinoids, today announced its financial results for the three months ended September 30, 2022 . Q3 2022 – Select Recent Operating Highlights Strong Revenue Growth Quarterly net revenue of $7.3M , an increase of 66% on a... Read More

BARRIE, ON , Nov. 9, 2022 /CNW/ - MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) ("MediPharm" or the "Company") a pharmaceutical company specialized in precision-based cannabinoids, is pleased to announce it will release second quarter financial results for the three and nine month period ended September 30, 2022, before markets open on Monday, November 14, 2022. MediPharm's executive management team will also... Read More

MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) ("MediPharm Labs" or the "Company") a pharmaceutical company specialized in precision-based cannabinoids, completed the sale of MediPharm Labs Australia Pty ("MediPharm Labs Australia"), a fully owned subsidiary of the Company, for a value of $7.25M AUD ( $6 .3M CAD) (the "Sale"). The sale was completed with OneLife Botanicals PTY ("OneLife Botanicals") effective... Read More

MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company") a pharmaceutical company specialized in precision-based cannabinoids, today announced its financial results for the three and six months ended June 30, 2022 . Q2 2022 – Select Recent Operating Highlights Streamlining and Focusing Operations On April 20 th , experienced Pharma and Med Tech executive David Pidduck was... Read More

MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) ("MediPharm" or the "Company") a pharmaceutical company specialized in precision-based cannabinoids, is pleased to announce it will release second quarter financial results for the three and six month period ended June 30, 2022 before markets open on Monday, August 15, 2022. MediPharm's executive management team will also host a conference call and audio webcast on... Read More

MediPharm to design, manufacture and supply a liquid oral cannabis study drug for the Phase 2 Life's end Benefits of cannabidiol and tetrahydrocannabinol (LiBBY) study, to be conducted in the U.S., across 20 sites. The lead investigators have been awarded a total of US$16M grant from the US National Institutes of Health and the National Institute on Aging to support the research project. MediPharm Labs Corp. (TSX: LABS)... Read More

MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company") a pharmaceutical company specialized in precision-based cannabinoids, today announced that it has been awarded a favourable summary of judgement in the Ontario Court of Justice in connection with a supply agreement dispute in the amount of $9.8M . On January 24, 2020 , MediPharm Labs filed a statement of claim... Read More

MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) ("MediPharm Labs" or the "Company") a pharmaceutical company specialized in precision-based cannabinoids, has entered into a Share Purchase Agreement (the "Agreement") with OneLife Botanicals PTY ("OneLife Botanicals") for the sale of MediPharm Labs Australia Pty Ltd ("MPLA"), a wholly-owned subsidiary of the Company, for a minimum value of $6.9M AUD ( $6.2M CAD).... Read More

MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) ("MediPharm Labs" or the "Company") a pharmaceutical company specialized in precision-based cannabinoids, today announced the results of matters voted on at its annual meeting of holders of common shares held on Thursday, June 30, 2022 (the "Meeting"). The voting results for each of the matters presented at the Meeting are outlined below. There were 293 shareholders... Read More

MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company") a pharmaceutical company specialized in precision-based cannabinoids, today announced its financial results for the three months ended March 31, 2022 . Q1 2022 – Select Operating Highlights Continued leadership in global cannabis pharmaceuticals – poised to grow in U.S. market In Q1, MediPharm entered the United States... Read More

MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) ("MediPharm" or the "Company") a pharmaceutical company specialized in precision-based cannabinoids, is pleased to announce it will release fourth quarter financial results for the three month period ended March 31, 2022 before markets open on Monday, May 16, 2022. MediPharm's executive management team will also host a conference call and audio webcast on Monday, May... Read More

MediPharm Labs Corp . (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) ("MediPharm Labs", "MediPharm" or the "Company") a pharmaceutical company specializing in precision-based cannabinoids, today announced that it has appointed experienced Pharma and Med Tech executive David Pidduck as Chief Executive Officer and Director of the... Read More

Naturally derived oil and inhalable cannabigerol ("CBG") products added to MediPharm's wellness portfolio – the benefits of CBG without the effects of THC. New CBG products include Advanced Formula, which is a CBG:CBD 1:2 oil, and Northbound, which is a high CBG vape cartridge with CBD inspired by The White and Appalachia... Read More

MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company") a pharmaceutical company specialized in precision-based cannabinoids, today announced its financial results for the three and twelve months ended December 31, 2021 . 2021 – Select Operating Highlights Expanded international footprint International sales more than doubled in 2021, to $9.5 million (44% of Revenue),... Read More

MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) ("MediPharm" or the "Company") a pharmaceutical company specialized in precision-based cannabinoids, is pleased to announce it will release fourth quarter financial results for the three and twelve month period ended December 31, 2021 after markets close on Thursday,... Read More

Known for its high-quality, specialty recreational dried flower products, Shelter Cannabis is expected to complement MediPharm's existing Canadian cannabis portfolio. Adds IP and well-regarded Shelter brands Wildlife and Shelter Craft to MediPharm. MediPharm expects to leverage its recently expanded national sales network to... Read More

Completed a Drug Master File ("DMF") process for CBD Active Pharmaceutical Ingredient ("API") for the US Federal Drug Administration ("FDA"). Use of Canadian Drug Establishment Licence ("DEL") to register API with the FDA for commercial opportunities in pharmaceutical development, novel drugs and generic drugs. The... Read More

MediPharm Labs Corp. (TSXV: LABS) (OTCQX: MEDIF) (FSE: MLZ) (“MediPharm Labs” or the “Company”) a pharmaceutical company specialized in precision-based cannabinoids, is pleased to announce that it has completed all payments required under its 2020 $41 million unsecured convertible debt. “MediPharm continues on its plan and path to profitability, and paying off our convertible debt in full is a major milestone on that path,”... Read More

MediPharm Labs pharma-quality CBD dominant oil line has been awarded CBD Brand of the year by KIND Magazine. MediPharm Labs’ CBD products have seen steady revenue growth and notoriety in 2021, including on national television on an episode of CBC Marketplace. MediPharm Labs Corp . (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ)... Read More

Strong cash balance and continued reduction of convertible debt to less than $500K. Opportunities for optimization of the operating strategy between Australia and Canada as the Canadian Drug Establishment Licence (DEL) unlocks many manufacturing and supply chain pathways. These pathways will reduce infrastructure cost, improve delivery times, and increase customer satisfaction. Delivery to five international medical cannabis... Read More

MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) (“MediPharm Labs” or the “Company”) a pharmaceutical company specialized in precision-based cannabinoids, is pleased to announce changes to its Board of Directors (the “Board”). Effectively immediately, Pat McCutcheon, Warren Everitt and Keith Strachan will be resigning from the Board. The change is being made as a next step in the Company’s transformation to an... Read More

Patient based delivery of medical cannabis executed with approval from both Barbados and Canadian Health Authorities. This marks the fourth new country entered by MediPharm Labs in 2021, following initial shipments to Germany, Brazil and Peru. MediPharm Labs Corp . (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) (“MediPharm Labs” or the “Company”) a pharmaceutical company specialized in precision-based cannabinoids, is pleased to... Read More

A leader in CBN products, MediPharm Labs, adds CBN:CBD products to its wellness portfolio for consumers and patients looking for a product without THC effects. New CBN products include CBN:CBD 1:2 Relax Formula Oil and a Northbound high CBN and high CBD vape cartridge. MediPharm Labs Corp . (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) (“MediPharm Labs” or the “Company”) a pharmaceutical company specialized in precision-based... Read More

MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) (“MediPharm” or the “Company”) a pharmaceutical company specialized in precision-based cannabinoids today announced its financial results for the three and nine months ended September 30, 2021, a period of transition in establishing itself as an international pharmaceutical company specializing in cannabis. Q3 2021 Key Highlights Received North America’s sole Drug... Read More

MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE:MLZ) (“MediPharm Labs” or the “Company”) a pharmaceutical company specialized in precision-based cannabinoids, is pleased to announce it will release third quarter financial results for the three and nine month period ended September 30, 2021 before markets open on Monday, November 15, 2021. MediPharm Labs executive management team will also host a conference call and... Read More

C-Suite healthcare leader, Bryan Howcroft, to lead MediPharm’s next phase of international growth as CEO. Bryan will apply his experience in registering, distributing, and selling medically registered products in the United States, European Union and other global markets. MediPharm Labs Corp . (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) (“MediPharm Labs” or the “Company”) a pharmaceutical company specialized in precision-based... Read More

New strategic partnership through the delivery of GMP extract to Germany for Vayamed, the medical cannabis business unit of Sanity Group Vayamed is a well-established operating medical cannabis company in Germany, where the medical cannabis market is expected to be worth €7.7 billion by 2028 according to Forbes MediPharm Labs Corp . (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) (“MediPharm Labs” or the “Company”) a pharmaceutical... Read More

McMaster University researchers using MediPharm Labs’ CBD50 formula and a CBD:THC 10:2 formulation, which has the same cannabinoid ratio as MediPharm Labs’ CBD25:, have received a No Objection Letter from Health Canada to begin recruiting human subjects for a placebo-controlled trial using cannabis- oil for treatment of insomnia in major depressive disorder. Among those with depression, 75% have difficulty falling or staying... Read More

Received first instalment of a government grant for $330,000AUD as part of the Australian government’s Manufacturing Modernisation program aimed at supporting manufacturers scaling their businesses. Grant to be used for automation of downstream manufacturing and scaling purification abilities. Government grant as part of broader manufacturing sector funding demonstrates the backing of the medical cannabis industry by the... Read More

Completed the regulatory process required to ship medical cannabis to Brazil with import permits issued from ANVISA and export permits issued from Health Canada. Initial deliveries will be under the compassionate care program. First shipments to Brazil to be used for patient trials to collect data that may be used in future product marketing authorizations under Brazil’s medical cannabis program. A program that saw over... Read More

BARRIE, Ontario, Aug. 16, 2021 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) (“MediPharm” or the “Company”) a pharmaceutical company specialized in research-driven development and manufacturing of cannabis API and finished dose products today announced its financial results for the three and six months ended June 30, 2021, a period of ongoing progress in establishing itself as an... Read More

MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) (“MediPharm Labs” or the “Company”) a pharmaceutical company specialized in research-driven development and manufacturing of cannabis API and finished products, is pleased to announce it will release second quarter financial results for the three and six month period ended June 30, 2021 before markets open on Monday, August 16, 2021. MediPharm Labs executive... Read More

Health Canada Drug Establishment Licence allows MediPharm Labs to conduct pharmaceutical manufacturing and sale of Active Pharmaceutical Ingredients and Pharmaceutical Drug Products Makes MediPharm Labs a full-service pharmaceutical company that can support the global pharma entry into the drugs containing cannabis market, including in the US First domestic GMP Licence in North America for cannabis-related pharmaceutical... Read More

MediPharm Labs’ Cannabis Drug Licence and expertise qualifies and positions the Company to supply clinical trial material, assist in investigation protocol and provide regulatory support for multiple trials Three initial proposed clinical trials will evaluate the effectiveness of proprietary THC and CBD drug candidates for multiple indications including Pain, Insomnia associated with Major Depression, and Uremic Pruritus.... Read More

MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) (“MediPharm Labs” or the “Company”) a global leader in specialized, research-driven pharmaceutical-quality cannabis extraction, distillation and derivative products, today announced the results of matters voted on at its annual meeting of holders of common shares held on Wednesday, June 9, 2021 (the “Meeting”). The voting results for each of the matters presented at... Read More

MediPharm and ADREXpharma continue to lead the way addressing rising patient demand in the burgeoning German Medical Cannabis Market that saw sales increase 34% last year 128,000 active patients at end of 2020; German patients spent an average of $500EUR per month, finished products and extract sales continue to gain market share MediPharm and ADREXpharma on track to deliver subsequent shipments to Germany in Q2 2021,... Read More

BARRIE, Ontario, May 27, 2021 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) (“MediPharm Labs” or the “Company”) a global leader in specialized, research-driven pharmaceutical-quality cannabis extraction, distillation and derivative products, today announced it launched its first wellness products in Quebec and shipped its first order of premium CBD oils for retail sale to the Société... Read More

MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) (“MediPharm Labs” or the “Company”) a global leader in specialized, research-driven pharmaceutical-quality cannabis extraction, distillation and derivative products, today announced it launched its first wellness products in Quebec and shipped its first order of premium CBD oils for retail sale to the Société québécoise du cannabis (SQDC), the province’s sole legal... Read More

MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) (“MediPharm” or the “Company”) a global leader in specialized, research-driven cannabis extraction, distillation and derivative products today announced its financial results for the three months ended March 31, 2021, a period of ongoing progress in establishing itself as an international pharmaceutical company, specializing in cannabis. First Quarter Overview “We... Read More

MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE:MLZ) (“MediPharm Labs” or the “Company”) a global leader in specialized, research-driven pharmaceutical-quality cannabis extraction, distillation and derivative products, is pleased to announce it will release first quarter financial results for the three month period ended March 31, 2021 before markets open on Monday, May 17, 2021. MediPharm Labs executive management team... Read More

MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) (“MediPharm Labs” or the “Company”) a global leader in specialized, research-driven pharmaceutical-quality cannabis extraction, distillation and derivative products, today announced through its wholly owned subsidiary, it has signed a new agreement with MT Pharma, based in Malta to supply premium, GMP certified, finished dose cannabis oil for patients. MediPharm Labs... Read More

MediPharm Labs’ high THC medical cannabis has been successfully exported to Peru for distribution by specialized compounding pharmacies Peru marks MediPharm Labs’ first Latin American export following successful exports to Australia and Germany MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) (“MediPharm Labs” or the “Company”), a global leader in specialized, research-driven pharmaceutical-quality cannabis... Read More

MediPharm Labs exports commercial shipment of medical cannabis products approved by the Australian Therapeutic Goods Administration (TGA) to patients in Germany An export milestone for the Australian cannabis industry as an export hub Germany is one of the most heavily regulated export markets in the world, this export milestone strengthens MediPharm Labs’ and Australia's position as a leader in medical cannabis production... Read More

MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) (“MediPharm Labs”) a global leader in specialized, research-driven pharmaceutical-quality cannabis extraction, distillation and derivative products, today announced STADA Arzneimittel AG (STADA) , a leading European consumer health and generics company, and MediPharm Labs, under an exclusive, turnkey supply agreement, have commenced sales in Germany. As a result,... Read More

MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) (“MediPharm Labs” or the “Company”) a global leader in specialized, research-driven cannabis extraction, distillation and derivative products today announced its financial results for the three and twelve months ended December 31, 2020. “We are executing on our strategy to become a high-value, GMP-certified, global cannabis API provider to medical and wellness... Read More

MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE:MLZ) (“MediPharm Labs” or the “Company”) a global leader in specialized, research-driven pharmaceutical-quality cannabis extraction, distillation and derivative products, is pleased to announce it will release fourth quarter financial results for the three and twelve month period ended December 31, 2020 before markets open on Wednesday, March 31, 2021. MediPharm Labs... Read More

MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) (“MediPharm Labs” or the “Company”) a global leader in specialized, research-driven pharmaceutical-quality cannabis extraction, distillation and derivative products, today announced a further expansion of its innovative, pharma-quality family of branded products with... Read More

Quebec marks the Company’s 7 th provincial distribution supply agreement MediPharm Labs expanded distribution footprint represents potential coverage of an estimated 95%+ of retail market in Canada MediPharm Labs will be selling its MediPharm Labs and LABS Cannabis product lines in Quebec MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE:MLZ) (“MediPharm Labs” or the “Company”) a global leader in specialized,... Read More

MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) (“MediPharm Labs” or the “Company”), a global leader in specialized, research-driven cannabis extraction, distillation and derivative products, is pleased to announce its wholly owned subsidiary, MediPharm Labs Australia Pty Ltd (“MediPharm Labs Australia”), has entered into a new GMP white-label supply and contract manufacturing agreement with Cannim Australia Pty... Read More

MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE:MLZ) (“MediPharm Labs” or the “Company”) a global leader in specialized, research-driven pharmaceutical-quality cannabis extraction, distillation and derivative products, is pleased to announce the closing of its previously announced “bought deal” offering of units of the Company (the “Units”) for total gross proceeds of $33,350,000. The Company sold 57,500,000 Units at a... Read More

MediPharm Labs Corp . (TSX: LABS) (OTCQX: MEDIF) (FSE:MLZ) (“MediPharm Labs” or the “Company”) a global leader in specialized, research-driven pharmaceutical-quality cannabis extraction, distillation and derivative products, is pleased to announce that it has agreed to increase the size of its previously announced “bought deal” offering of units of the Company (the “Units”) led by Cantor Fitzgerald Canada Corporation, as... Read More

MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE:MLZ) (“MediPharm Labs” or the “Company”) a global leader in specialized, research-driven pharmaceutical-quality cannabis extraction, distillation and derivative products, is pleased to announce that it has entered into an agreement with Cantor Fitzgerald Canada Corp., as lead underwriter and sole bookrunner on behalf of a syndicate of underwriters (collectively the... Read More

MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) (“MediPharm Labs” or the “Company”), a global leader in specialized, research-driven cannabis extraction, distillation and derivative products, announced it has received a Cannabis Drug Licence (“CDL licence”) from Health Canada. The CDL licence is a critical licence required in the qualification for MediPharm Labs to manufacture and supply drugs that contain... Read More

MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE:MLZ) (“MediPharm Labs” or the “Company”) a global leader in specialized, research-driven pharmaceutical-quality cannabis extraction, distillation and derivative products, is pleased to announce Greg Hunter will join MediPharm Labs as Chief Financial Officer (CFO), effective February 8, 2021. Greg Hunter brings over 20 years of experience as a business executive holding... Read More